Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip (ECHODIAH)

Laboratoires NEGMA

Status and phase

Completed

Phase 3

Conditions

Hip Osteoarthritis

Treatments

Drug: diacerein

Study type

Interventional

Funder types

Industry

Identifiers

HEC / CHO 90040N

AFSSAPS number: 930289

CCPPRB number: 469

Details and patient eligibility

About

We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to:

evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis
to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis

This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery

Sex

All

Ages

50 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Outpatients fulfilling the American College of Rheumatology criteria for the diagnosis of hip osteoarthritis.
Lequesne algofunctional index of at list 3 points.
Radiographic criterion for inclusion: joint space width (JSW) between 1 mm and 3 mm. If the JSW exceeded 3 mm, it had to be at least 0.5 mm thinner than JSW of the contra lateral hip, measured at its narrowest point.

Exclusion criteria

Intraarticular injection or arthroscopy of the hip during the three months prior to inclusion in the study.
Any systemic or intraarticular corticosteroid as well as other potential symptom-modifying drugs for osteoarthritis were not allowed during the study.